Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts

Lung Cancer

Volumn 76, Issue 1, 2012, Pages 39-45

  Mousa, Shaker A ^a,b   Yalcin, Murat ^a,c   Bharali, Dhruba J ^a   Meng, Ran ^d   Tang, Heng Yuan ^d   Lin, Hung Yun ^d   Davis, Faith B ^d   Davis, Paul J ^d,e  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c ULUDAG UNIVERSITY   (Turkey)

^d ORDWAY RESEARCH INSTITUTE   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Angiogenesis; Cancer; Cell surface integrin v 3 receptor; Non small cell lung cancer; Tetrac; Tetrac nanoparticles; Thyroid hormone

Indexed keywords

LIOTHYRONINE; MITOGEN ACTIVATED PROTEIN KINASE; NANOPARTICLE; TETRAIODOTHYROACETIC ACID; TETRAIODOTHYROACETIC ACID NANOPARTICLE; THYROMIMETIC AGENT; THYROXINE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL PROLIFERATION; CHICK; CHORIOALLANTOIS; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INTEGRIN ALPHAVBETA3; LUNG NEOPLASMS; MICE; MICE, NUDE; NANOPARTICLES; THYROID HORMONES; THYROXINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84858003654     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.10.003     Document Type: Article

References (46)

1. American Lung Association (Epidemiology and Statistics Unit). Trends Lung Cancer Morb Mortal 2010 (March). Available at: http://www.lungusa.org/finding-cures/our-research/trend-reports/lc-trend-report.pdf.
2. Carney D.N. Chemotherapy in the management of subjects with inoperable non-small cell lung cancer. Semin Oncol 1996, 6(Suppl.):71-75.
3. Subramanian J., Morgansztern D., Govindan R. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Lung Cancer 2010, 11:311-319.
4. Bertino E.M., Otterson G.A. Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer. Lung Cancer 2010, 70:233-246.
5. Langer C., Soria J.C. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer. Clin Lung Cancer 2010, 11:82-90.
6. Travis W.D., Travis L.B., Devesa S.S. Lung cancer. Cancer 1995, 75(Suppl. 1):191-202.
7. Cheng S.Y., Leonard J., Davis P.J. Molecular aspects of thyroid hormone actions. Endocr Rev 2010, 31:139-170.
8. Bergh J.J., Lin H.Y., Lansing L., Mohamed S.N., Davis F.B., Mousa S., et al. Integrin alpha v beta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005, 146:2864-2871.
9. Davis F.B., Mousa S.A., O'Connor L., Mohamed S., Lin H.Y., Davis P.J. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 2005, 94:1500-1506.
10. Mousa S.A., O'Connor L., Davis F.B., Davis P.J. Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated. Endocrinology 2006, 147:1602-1607.
11. Luidens M.K., Mousa S.A., Davis F.B., Lin H.Y., Davis P.J. Thyroid hormone and angiogenesis. Vasc Pharmacol 2010, 52(March-April (3-4)):142-145.
12. Davis F.B., Tang H.Y., Shih A., Keating T., Lansing L., Hercbergs A., et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res 2006, 66:7270-7275.
13. Lin H.Y., Tang H.Y., Shih A., Keating T., Cao J., Davis P.J., et al. Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids 2007, 72:180-187.
14. Cody V., Davis P.J., Davis F.B. Molecular modeling of the thyroid hormone interactions with alphavbeta3 integrin. Steroids 2007, 72:165-170.
15. Plow E.F., Haas T.A., Zhang L., Loftus J., Smith J.W. Ligand binding to integrins. J Biol Chem 2000, 275:21785-21788.
16. Gahmberg C.G., Fagerholm S.C., Nurmi S.M., Chavakis T., Marchesan S., Gronholm M. Regulation of integrin activity and signaling. Biochem Biophys Acta 2009, 1790:431-434.
17. Masson-Gadais B., Houle F., Laferriere J., Huot J., Integrin αvβ3, requirement for VEGFR2-mediated activation of SAPK2/p38 and Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones 2003, 8:37-52.
18. Sahni A., Francis C.W. Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires alphavbeta3. Blood 2004, 104(12):3635-3641.
19. Mousa S.A., Bergh J.J., Dier E., Rebbaa A., O'Connor L.J., Yalcin M., et al. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 2008, 11(2):183-190.
20. Lin H.Y., Sun M., Tang H.Y., Lin C., Luidens M.K., Mousa S.A., et al. l-Thyroxine vs. 3,5,3'-triiodo-l-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 2009, 296:C980-C991.
21. Davis P.J., Davis F.B., Lin H.Y., Mousa S.A., Zhou M., Luidens M.K. Translational implication of nongenomic actions of thyroid hormone initiated at its integrin receptor. Am J Physiol Endocrinol Metab 2009, 297:E1238-E1246.
22. Davis P.J., Davis F.B., Mousa S.A., Lin H.Y. Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Ann Rev Pharmacol Toxicol 2011, 51(February):99-115.
23. D'Arezzo S., Incerpi S., Davis F.B., Aconcia F., Marino M., Farias R.N., et al. Rapid non-genomic effects of 3,5,3(-triiodo-l-thyronine on the intracellular pH of L-6 myoblasts is mediated by intracellular calcium and kinase pathways. Endocrinology 2004, 145:5694-5703.
24. Rebbaa A., Chu F., Davis F.B., Davis P.J., Mousa S.A. Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemo-sensitizing and anti-cancer agent. Angiogenesis 2008, 11(3):269-276.
25. Lin H.Y., Landersdorfer C.B., London D., Meng R., Lim C.U., Lin C., et al. Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system. PLoS Comput Biol 2011, 7(February (2)):e1001073.
26. Yalcin M., Bharali D.J., Lansing L., Dyskin E., Mousa S.S., Hercbergs A., et al. Tetraiodothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res 2009, 29:3825-3831.
27. Yalcin M., Dyskin E., Lansing L., Bharali D.J., Mousa S.S., Bridoux A., et al. Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of human medullary carcinoma of the thyroid. J Clin Endocrinol Metab 2010, 95:1972-1980.
28. Yalcin M., Bharali D.J., Dyskin E., Dier E., Lansing L., Mousa S.S., et al. Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma. Thyroid 2010, 20:281-286.
29. Moreno M., de lange P., Lombardi A., Silvestri E., Lanni A., Goglia F. Metabolic effects of thyroid hormone derivatives. Thyroid 2008, 18:239-253.
30. Bridoux A., Cui H., Dyskin E., Yalcin M., Mousa S.A. Semisynthesis and pharmacological activities of tetrac analogs: angiogenesis modulators. Bioorg Med Chem Lett 2009, 19(June (12)):3259-3263.
31. Glinskii A.B., Glinsky G.V., Lin H.Y., Teng H.Y., Sun M., Davis F.B., et al. Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 2009, 8:3554-3562.
32. Jeffery H., Davis S.S., Ohagan D.T. The preparation and characterization of poly (lactide-co-glycolide) microparticles. 1. Oil-in-water emulsion solvent evaporation. Int J Pharm 1991, 77(2-3):169-175.
33. Song C.X., Labhasetwar V., Qu X., Humphery W.R., Shebuski R.J., Levi R.J. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J Control Release 1997, 43(2-3):197-212.
34. Hermanson G.T. Bioconjugate technique 1996, Academic Press, San Diego, CA, p. 617-8.
35. Mousa S.S., Mousa S.A. Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancer. J Cell Biochem 2006, 97(6):1370-1378.
36. Goodman A.D., Hoekstra S.J., Marsh P.S. Effects of hypothyroidism on the induction and growth of mammary cancer induced by 7,12-dimethylbenz (a) anthracene in the rat. Cancer Res 1980, 40:2336-2342.
37. Theodossiou C., Skrepnik N., Robert E.G., Prasad C., Axelrad T.W., Schapira D.V., et al. Propylthiouracil-induced hypothyroidism reduces xenograft tumor growth in athymic nude mice. Cancer 1999, 86(8):1596-1601.
38. Hercbergs A.H., Goyal L.K., Suh J.H., Reddy C.A., Cohen B.H., Stevens G.H., et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Res 2003, 23:617-626.
39. Cristofanilli M., Yamamura Y., Kau S.W., Bevers T., Strim S., Patangan M., et al. Thyroid hormone and breast carcinoma. Cancer 2005, 103:1122-1128.
40. Schmidinger M., Vogl U.M., Bojic M., Lamm W., Heinzl H., Haitel A., et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?. Cancer 2011, 117(February (3)):534-544.
41. Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M, Mazzanti R. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol 2010;Sep 28, , [epub ahead of print]. doi:10.1016/j.urolonc.2010.07.015.
42. Hercbergs A.H., Ashur-Fabian O., Gardield D. Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology. Curr Opinion Endocrinol Diabetes Obes 2010, 17:432-436.
43. Prati M., Calvo R., Morreale G., Morreale de Escobar G. l-Thyroxine and 3,3,5-triiodothyronine concentrations in the chicken egg and in the embryo before and after the onset of thyroid function. Endocrinology 1992, 130:2651-2659.
44. Lin H.Y., Tang H.Y., Keating T., Wu Y.H., Shih A., Hammond D., et al. Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK-mediated. Carcinogenesis 2008, 29:62-69.
45. Lin H.Y., Davis P.J., Mousa S.A., Tang H.Y., Hercbergs A.H., Davis F.B. The pro-apoptotic action of stilbene-induced COX-2 in cancer cells. Convergence with the anti-apoptotic effect of thyroid hormone. Cell Cycle 2009, 8:1877-1882.
46. Burger A.G., Engler D., Sakoloff C., Staeheli V. The effects of tetraiodothyroacetic and triiodothyroacetic acids on thyroid function in euthyroid and hyperthyroid subjects. Qcta Endocrinol (Copenh) 1979, 92:455-467.